secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silence Therapeutics plc (SLN)
CIK:        0001479615
Form:       8-K
Filed at:   2025-12-22T23:59:59+00:00
Accession:  0001193125-25-327575
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Silence Therapeutics appoints CFO Rhonda Hellums to Board of Directors effective Dec 18, 2025
--------------------------------------------------------------------------------

- Rhonda Hellums, EVP and CFO, appointed as executive director effective December 18, 2025.
- Her initial term runs until the 2026 Annual General Meeting of Shareholders.
- Ms. Hellums will not receive additional compensation for board service.
- She will not serve on any board committee.
- No family relationships or material transactions requiring disclosure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479615/000119312525327575/0001193125-25-327575-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479615/000119312525327575/sln-20251218.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-327575

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer